A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH. METHODS: In this phase 2b, double-blind, randomized, placebo-controlled trial, patients with noncirrhotic, highly active NASH were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of lanifibranor or placebo once daily for 24 weeks. The primary end point was a decrease of at least 2 points in the SAF-A score (the activity part of the Steatosis, Activity, Fibrosis [SAF] scoring system that incorporates scores for ballooning and inflammation) without worsening of fibrosis; SAF-A scores range from 0 to 4, with higher scores indicating more-severe disease activity. Secondary end points included resolution of NASH and regression of fibrosis. RESULTS: A total of 247 patients underwent randomization, of whom 103 (42%) had type 2 diabetes mellitus and 188 (76%) had significant (moderate) or advanced fibrosis. The percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher among those who received the 1200-mg dose, but not among those who received the 800-mg dose, of lanifibranor than among those who received placebo (1200-mg dose vs. placebo, 55% vs. 33%, P = 0.007; 800-mg dose vs. placebo, 48% vs. 33%, P = 0.07). The results favored both the 1200-mg and 800-mg doses of lanifibranor over placebo for resolution of NASH without worsening of fibrosis (49% and 39%, respectively, vs. 22%), improvement in fibrosis stage of at least 1 without worsening of NASH (48% and 34%, respectively, vs. 29%), and resolution of NASH plus improvement in fibrosis stage of at least 1 (35% and 25%, respectively, vs. 9%). Liver enzyme levels decreased and the levels of the majority of lipid, inflammatory, and fibrosis biomarkers improved in the lanifibranor groups. The dropout rate for adverse events was less than 5% and was similar across the trial groups. Diarrhea, nausea, peripheral edema, anemia, and weight gain occurred more frequently with lanifibranor than with placebo. CONCLUSIONS: In this phase 2b trial involving patients with active NASH, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher with the 1200-mg dose of lanifibranor than with placebo. These findings support further assessment of lanifibranor in phase 3 trials. (Funded by Inventiva Pharma; NATIVE ClinicalTrials.gov number, NCT03008070.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both have been tested successfully on phase II clinical trials, proving they are well-tolerated by patients and showing MASH resolution without worsening of fibrosis (165, 166).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [166]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most importantly, resolution of NASH without worsening of fibrosis (49% with 1200 mg Lanifibranor, vs. 39% with 800 mg vs. 22% Placebo), improvement in fibrosis of at least one stage without worsening of NASH (48% vs. 34% vs. 22%) and resolution of NASH plus improvement in fibrosis stage of at least 1 (35% vs. 25% vs. 9%) all favored the study drug as compared to placebo.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The pan-PPAR agonist lanifibranor demonstrated significant MASH resolution and fibrosis improvement in clinical trials, though it was associated with weight gain [3,136].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [136]
The cited source says what the claim attributes to it.
In the citing paper
“Diarrhea, nausea, peripheral edema, anemia and weight gain were all seen more frequently in patients receiving Lanifibranor [59].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
The cited source says what the claim attributes to it.
In the citing paper
“Finally and most recently the Pan‐PPAR agonist Lanifibranor reached the primary endpoint of a decrease in SAF‐A score of at least two points in a large Phase 2b Trial [59]—a dose‐dependent effect was seen with more patients achieving the primary endpoint with 1200 mg versus 800 mg.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationGlobal burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 4×
“Increase in aminotransferase level§§ 3 (4) 5 (6) 1 (1)”
InfluentialSelf-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citationDulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Self-citationYounossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Self-citationNon-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
Yki-Järvinen, H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70032-4 · Cited by 1,259 · cited 1×
“Adverse event related to active drug or placebo, during the treatment period, as assessed by the investigator 23 (28) 25 (30) 19 (23)”
Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802 · cited 1×
“Adverse event related to active drug or placebo, during the treatment period, as assessed by the investigator 23 (28) 25 (30) 19 (23)”
Self-citationFriedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671
Self-citation
Research works printed but not linked: 2
- Sanyal AJ Anstee QM Trauner M et al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis (NASH). Hepatology 2020;72:67A-68A. abstract 90.
- Ratziu V de Guevara L Safadi R et al. Aramchol in patients with nonalcoholic steatohepatitis: a randomized double-blind placebo-controlled phase 2b trial. Nat Med (in press).
Cited by
Items 101–200 of 830
Wang, L., Yan, Y., Wu, L., & Peng, J. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106925 · Cited by 83
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Kokkorakis, M., Muzurović, E., Volčanšek, Š., Chakhtoura, M., Hill, M. A., Mikhailidis, D. P., & Mantzoros, C. S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001087 · Cited by 76
Lonardo, A., Mantovani, A., Targher, G., & Baffy, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113320 · Cited by 85
“Outcome/Drug Vitamin E [113] Pioglitazone [113] Obeticholic Acid [114] Resmetirom [115] Semaglutide [116] Lanifibranor [117] Aldafermin [118] Elafibranor [119] Cenicriviroc [120] Selonsertib [121–123]”
BackgroundCooreman, M. P., Butler, J., Giugliano, R. P., Zannad, F. M., Dzen, L., Huot-Marchand, P., Baudin, M., Beard, D. R., Junien, J., Broqua, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47919-9 · Cited by 83
Self-citationNg, C. H., Huang, D. Q., & Nguyen, M. H. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0070 · Cited by 82
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Genua, I., & Cusi, K. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0012 · Cited by 77
Antioxidant and anti-inflammatory agents in chronic liver diseases: Molecular mechanisms and therapy
Zhang, C.-Y., Liu, S., & Yang, M. J. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i2.180 · Cited by 81
Díaz, L. A., Arab, J. P., Idalsoaga, F. J., Perelli, J., Vega, J. A., Dirchwolf, M., Carreño, J., Samith, B., Valério, C. M., Moreira, R. O., et al. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101903 · Cited by 86
Zhou, S., You, H., Qiu, S., Yu, D., Bai, Y., He, J., Cao, H., Che, Q., Guo, J., & Su, Z. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113577 · Cited by 80
Kamata, S., Honda, A., & Ishii, I. (2023) · Biomolecules · doi:10.3390/biom13081264 · Cited by 81
“worsening of fibrosis was significantly higher with a 1200 mg/day lanifibranor dose than with placebo [17,18].”
BackgroundNoninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Reinson, T., Buchanan, R. M., & Byrne, C. D. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0348 · Cited by 75
Musso, G., Saba, F., Cassader, M., & Gambino, R. (2023) · Progress in Lipid Research · doi:10.1016/j.plipres.2023.101238 · Cited by 74
Michalopoulou, E., Thymis, J., Lampsas, S., Pavlidis, G., Katogiannis, K., Vlachomitros, D., Katsanaki, E., Kostelli, G., Pililis, S., Pliouta, L., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020428 · Cited by 76
“…is a pan-PPAR agonist evaluated in the Phase II NATIVE trial, which demonstrated significant results in achieving NASH resolution, reversing fibrosis, and improving both lipid profiles and insulin sensitivity in adult patients with non-cirrhotic MASH after just 24 weeks of treatment [193].”
Lin, R., Sun, Q., Xin, X., Ng, C. H., Valenti, L. V. C., Hu, Y., Zheng, M., & Feng, Q. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156043 · Cited by 73
Fructose impairs fat oxidation: Implications for the mechanism of western diet-induced NAFLD
Inci, M. K., Park, S., Helsley, R. N., Attia, S. L., & Softic, S. (2022) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2022.109224 · Cited by 69
Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy
(2024) · doi:10.1146/annurev-pharmtox-020524-012013 · Cited by 64
Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis
Angelini, G., Panunzi, S., Castagneto‐Gissey, L., Pellicanò, F., Gaetano, A. D., Pompili, M., Riccardi, L., Garcovich, M., Raffaelli, M., Ciccoritti, L., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-327498 · Cited by 66
Targeting the FGF19–FGFR4 pathway for cholestatic, metabolic, and cancerous diseases
Li, X., Lu, W., Kharitonenkov, A., & Luo, Y. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13767 · Cited by 70
Armandi, A., & Bugianesi, E. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.01.005 · Cited by 68
“%) was observed as stigmata of γ -effect [37].”
Self-citationGong, L., Wei, F., Gonzalez, F. J., & Li, G. (2023) · Hepatology · doi:10.1097/hep.0000000000000182 · Cited by 71
The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease
Yang, Z., Danzeng, A., Liu, Q., Zeng, C., Xu, L., Mo, J., Ciren, P., Wang, X., Wang, C., Zhang, B., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.87305 · Cited by 66
“Likewise, in a phase Ⅱ clinical trial of Lanifibranor, there is evidence supporting its potential to provide benefits regarding numerous secondary endpoints, including hepatic fibrosis, lipid profile, and glycemic control[119].”
BackgroundYang, M., Wang, J., Xiao, W., & Fan, X. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1410668 · Cited by 74
Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis
Wang, M., Li, L., Xu, Y., Du, J., & Ling, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.958428 · Cited by 69
“Pioglitazone, a PPARγ-specific agonist; elafibranor, a dual PPARα/δ agonist; and lanifibranor, a PPARα/δ/γ/ are all under clinical trials (Sanyal et al., 2010; Ratziu et al., 2016; Francque et al., 2021).”
BackgroundTreating inflammation to combat non-alcoholic fatty liver disease
Wiering, L., & Tacke, F. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0194 · Cited by 56
Emerging pharmacological treatment options for MAFLD
Rojas, Á., Lara, C., Múñoz‐Hernández, R., Gato, S., Ampuero, J., & Romero‐Gómez, M. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221142452 · Cited by 59
Self-citationGries, J. J., Lazarus, J. V., Brennan, P., Siddiqui, M. S., Targher, G., Lang, C. C., Virani, S. S., Lavie, C. J., Isaacs, S. D., Arab, J. P., et al. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00310-8 · Cited by 68
“PPAR agonists, especially pioglitazone, have also been shown to decrease liver fat scores, liver fat accumulation product scores, and FIB-4 indices and improve or resolve histological features of MASH without worsening liver fibrosis 121-123 .”
Cariou, B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14651 · Cited by 62
“Modest body weight gain and peripheral oedema were observed with lanifibranor treatment.(117) These encouraging results need to be confirmed in the ongoing phase 3 clinical development programme.”
BackgroundAbdelmalek, M. F., Suzuki, A., Sanchez, W., Lawitz, E., Filozof, C., Cho, H., Baek, E., Choi, J., & Baek, S. (2023) · Contemporary Clinical Trials · doi:10.1016/j.cct.2023.107176 · Cited by 51
Self-citationMASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists
Cooreman, M. P., Vonghia, L., & Francque, S. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111688 · Cited by 59
Self-citationFougerat, A., Bruse, J., Polizzi, A., Montagner, A., Guillou, H., & Wahli, W. (2024) · Progress in Lipid Research · doi:10.1016/j.plipres.2024.101303 · Cited by 59
“In a phase 2 study, the pan PPAR-agonist lanifibranor has exhibited safety and efficacy in resolving MASH without worsening fibrosis in MASH patients [210].”
Maldonado-Rojas, A. D. C., Zuarth-Vázquez, J. M., Uribe, M., & Barbero-Becerra, V. J. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101182 · Cited by 60
MASH clinical trials and drugs pipeline: An impending tsunami
Noureddin, M. (2025) · Hepatology · doi:10.1097/hep.0000000000000860 · Cited by 48
Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
Александровна, П. В., Bezborodkina, N. N., & Okovityi, S. V. (2022) · Biomedicines · doi:10.3390/biomedicines10020274 · Cited by 58
Metabolic syndrome and its association with nonalcoholic steatohepatitis
Bril, F., Sanyal, A., & Cusi, K. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.002 · Cited by 52
Self-citationMASLD treatment—a shift in the paradigm is imminent
Machado, M. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1316284 · Cited by 51
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 70
Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH
Alkhouri, N., Beyer, C., Shumbayawonda, E., Andersson, A., Yale, K., Rolph, T., Chung, R. T., Vuppalanchi, R., Cusi, K. J., Loomba, R. S., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.031 · Cited by 60
Self-citationMASLD development: From molecular pathogenesis toward therapeutic strategies
Yang, Z., Zhao, J., Xie, K., Tang, C., Gan, C., & Gao, J. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003629 · Cited by 58
“[133] GLP-1/GIP/GCGR agonists Incretins are gastrointestinal hormones that enhance insulin secretion in response to food ingestion.”
Chew, N., Ng, C. H., Muthiah, M. D., & Sanyal, A. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01027-5 · Cited by 52
Self-citationKamata, S., Honda, A., Ishikawa, R., Akahane, M., Fujita, A., Kaneko, C., Miyawaki, S., Habu, Y., Shiiyama, Y., Uchii, K., et al. (2023) · Antioxidants · doi:10.3390/antiox12081523 · Cited by 46
“In a phase 2b study involving 247 patients with active NASH (NCT03008070), lanifibranor significantly improved general NASH conditions [41].”
BackgroundRecent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis
Jangra, A., Kothari, A., Sarma, P., Medhi, B., Omar, B. J., & Kaushal, K. (2022) · Cells · doi:10.3390/cells11091500 · Cited by 58
“In a multicenter, randomized, placebocontrolled trial [87,88] patients with NASH exhibited improvements in liver histological features after treatment.”
BackgroundSiddiqui, M. S., Parmar, D., Sheikh, F., Sarin, S. K., Cisneros, L., Gawrieh, S., Momin, T., Duseja, A., & Sanyal, A. J. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.01.018 · Cited by 42
Self-citationArmandi, A., Rosso, C., Caviglia, G. P., & Bugianesi, E. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156080 · Cited by 53
Self-citationMitochondria homeostasis: Biology and involvement in hepatic steatosis to NASH
Li, Y., Xie, Z., Song, Q., & Li, J.-Y. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00864-z · Cited by 55
“A recent phase 2b trial showed that lanifibranor treatment achieved significant therapeutic effects on NASH resolution and did not worsen fibrosis [164].”
BackgroundCircadian Regulation of Gene Expression and Metabolism in the Liver
Guan, D., & Lazar, M. A. (2022) · Seminars in Liver Disease · doi:10.1055/a-1792-4240 · Cited by 49
Jiang, Y., Wu, L., Zhu, X., Bian, H., Gao, X., & Xia, M. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02092-2 · Cited by 50
“In patients with MASLD, GLP-1R agonists, including dulaglutide [97], exenatide [98], lira-glutide [99] or semaglutide [100], have shown beneficial effects on hepatic fat content and liver histological inflammation and fibrosis, as listed in Table 3.”
BackgroundOsipova, D., Kokoreva, K., Лазебник, Л. Б., Голованова, Е. В., Pavlov, C. S., Духанин, А. С., Orlova, S., & Starostin, K. M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.797923 · Cited by 48
“However, a phase III study of elafibranor (RESOLVE-IT, NCT02704403) was terminated due to lack of efficacy, while lanifibranor showed promising results in phase IIb (Francque et al., 2021).”
BackgroundNonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery
Domingues, I., Leclercq, I. A., & Beloqui, A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.040 · Cited by 45
Liver biopsy evaluation in MASH drug development: Think thrice, act wise
Harrison, S. A., & Dubourg, J. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.008 · Cited by 53
Self-citationFeng, X., Zhang, R., Yang, Z., Zhang, K., & Xing, J. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00019 · Cited by 83
MetALD: Clinical aspects, pathophysiology and treatment
Gratacós‐Ginès, J., Ariño, S., Sancho‐Bru, P., Bataller, R. A., & Pose, E. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101250 · Cited by 62
Tantu, M. T., Farhana, F. Z., Haque, F., Koo, K. M., Qiao, L., Ross, A. G., & Shiddiky, M. J. A. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00030-2 · Cited by 57
Shared Mechanisms between Cardiovascular Disease and NAFLD
Huang, D. Q., Downes, M., Evans, R. M., Witztum, J. L., Glass, C. K., & Loomba, R. S. (2022) · Seminars in Liver Disease · doi:10.1055/a-1930-6658 · Cited by 47
Self-citationNonalcoholic Steatohepatitis Drug Development Pipeline: An Update
Chew, N., Ng, C. H., Truong, E., Noureddin, M., & Kowdley, K. V. (2022) · Seminars in Liver Disease · doi:10.1055/a-1877-9656 · Cited by 51
Role of hepatic peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease
Lee, S. M., Muratalla, J. T., Sierra‐Cruz, M., & Córdoba‐Chacón, J. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0155 · Cited by 49
Noureddin, M., Khan, S. M., Portell, F. R., Jorkasky, D. K., Dennis, J., Khan, O., Johansson, L., Johansson, E., & Sanyal, A. J. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00198-x · Cited by 46
Self-citationCurrent Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
Devasia, A. G., Ramasamy, A., & Leo, C. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041778 · Cited by 48
“Lanifibranor, a pan-PPAR agonist, was tested in a phase 2b trial with 247 patients with highly active MASH, showing significant liver histology improvements without worsening fibrosis [142,143]; a phase 3 trial (NCT04849728) with 1000 participants is ongoing to confirm these findings [144].”
Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis
Li, W., Alazawi, W., & Loomba, R. S. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00260-2 · Cited by 57
Self-citationUpdate of Indoles: Promising molecules for ameliorating metabolic diseases
Hu, W., Yan, G., Ding, Q., Cai, J., Zhang, Z., Zhao, Z., Lei, H., & Zhu, Y. Z. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112957 · Cited by 45
Bempedoic acid suppresses diet-induced hepatic steatosis independently of ATP-citrate lyase
Liu, J. Y., Kuna, R. S., Pinheiro, L. V., Nguyen, P. T., Welles, J. E., Drummond, J. M., Murali, N., Sharma, P. V., Supplee, J., Shiue, M., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.10.014 · Cited by 47
Nakamura, T., Masuda, A., Nakano, D., Amano, K., Sano, T., Nakano, M., & Kawaguchi, T. (2025) · Cells · doi:10.3390/cells14060428 · Cited by 47
“…trials and are good candidates for MASLD: GLP-1 receptor agonist, a dual agonist of glucagon receptor and GLP-1 receptor; pan-PPAR agonist; and FGF21 analog [78–84]. for MASLD: GLP-1 receptor agonist, a dual agonist of glucagon receptor GLP-1 receptor; pan-PPAR agonist; and FGF21 analog [78–84].”
Ratti, C., Malaguti, M., D’Aniello, E., Bellasi, A., & Sanna, G. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120495 · Cited by 46
Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders
Fiorucci, S., Urbani, G., Distrutti, E., & Biagioli, M. (2025) · Pharmaceuticals · doi:10.3390/ph18091424 · Cited by 47
Shen, W., Middleton, M. S., Cunha, G. M., Delgado, T. I., Wolfson, T. J., Gamst, A. C., Fowler, K. J., Alazraki, A. L., Trout, A. T., Ohliger, M. A., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.027 · Cited by 45
Self-citationMetALD: Does it require a different therapeutic option?
Marek, G. W., & Malhi, H. (2024) · Hepatology · doi:10.1097/hep.0000000000000935 · Cited by 43
“[67] Lanifibranor is currently still under investigation with further phase 2 and 3 studies, including the study of lanifibranor in combination with SGLT2 inhibitor empa-gliflozin for T2DM NCT05232071.”
Wang, S., Yin, J., Liu, Z., Liu, X., Tian, G., Xin, X., Qin, Y., & Feng, X. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123211 · Cited by 45
The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40
Torres-Peña, J. D., Larriva, A. P. A.-D., Alcala-Diaz, J. F., López‐Miranda, J., & Delgado‐Lista, J. (2023) · Nutrients · doi:10.3390/nu15061483 · Cited by 47
Dixon, E. D., Claudel, T., Nardo, A. D., Riva, A., Fuchs, C. D., Mlitz, V., Busslinger, G. A., Scharnagl, H., Stojaković, T., Séneca, J., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.09.037 · Cited by 41
Decoding organ fibrosis: mechanistic insights and emerging therapeutic strategies
Chen, X., Zhang, J., Guo, L., Wu, C., Zhou, J., Xu, M., Mo, L., Li, Y., & He, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02532-0 · Cited by 58
Pharmacological treatment of MASLD: contemporary treatment and future perspectives
Drygalski, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136518 · Cited by 39
“Lanifibranor, a pan-PPAR agonist activating α , γ , and δ isoforms, was investigated in two trials (NCT03008070 and NCT03459079) [88–91].”
Nonalcoholic Steatohepatitis — Opportunities and Challenges
García–Tsao, G. (2021) · New England Journal of Medicine · doi:10.1056/nejme2110989 · Cited by 40
Harnessing metabolism of hepatic macrophages to aid liver regeneration
Liu, R., Scimeca, M., Sun, Q., Melino, G., Mauriello, A., Shao, C., Bernassola, F., Bove, P., Candi, E., Valentina, R., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06066-7 · Cited by 48
MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials
Zannad, F. M., Sanyal, A. J., Butler, J., Ferreira, J. P., Girerd, N., Miller, V., Pandey, A., Parikh, C. R., Ratziu, V., Younossi, Z. M., et al. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13793 · Cited by 39
Self-citationVuppalanchi, R., Loomba, R. S., Sanyal, A. J., Nikooie, A., Tang, Y., Robins, D. A., Brouwers, B., & Hartman, M. L. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18042 · Cited by 38
Self-citationImpact of NAFLD and its pharmacotherapy on lipid profile and CVD
Wang, Z., Ye, M., Zhang, X., Zhang, P., Cai, J., Li, H., & She, Z. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.07.010 · Cited by 40
PPARα Senses Bisphenol S to Trigger EP300-Mediated Autophagy Blockage and Hepatic Steatosis
Liang, J., Xu, C. Y., Xu, J., Yang, C., Kong, W., Xiao, Z., Chen, X., Liu, Q., Weng, Z., Wang, J., et al. (2023) · Environmental Science & Technology · doi:10.1021/acs.est.3c05010 · Cited by 39
A roadmap for clinical trials in MASH-related compensated cirrhosis
Pericàs, J. M., Anstee, Q. M., Augustín, S., Bataller, R. A., Berzigotti, A., Ciudin, A., Francque, S., Abraldeṣ, J. G., Hernández–Gea, V., Pons, M., et al. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00955-8 · Cited by 41
Self-citationPharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances
Zhao, L., Tang, H., & Cheng, Z. (2024) · Pharmaceuticals · doi:10.3390/ph17121724 · Cited by 40
“Additionally, this study is the first clinical trial to demonstrate efficacy on composite histological endpoints for NASH resolution and fibrosis improvement [131].”
Resmetirom: The First Disease‐Specific Treatment for MASH
Mousa, A. M., Mahmoud, M., & AlShuraiaan, G. M. (2025) · International Journal of Endocrinology · doi:10.1155/ije/6430023 · Cited by 46
Zhang, Z., Yang, H., Han, F., & Guo, P. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47060464 · Cited by 43
“This mechanistic rationale may explain the anti-fibrotic effects observed in phase II/III trials [150,151].”
Wong, V. W., Amin, N. B., Takahashi, H., Darekar, A., Tacke, F., Kiszko, J., Rodriguez, H., Nakajima, A., Alkhouri, N., Charlton, M., et al. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00128-1 · Cited by 39
Self-citationDiet-derived antioxidants and nonalcoholic fatty liver disease: a Mendelian randomization study
Chen, L., Fan, Z., Sun, X., Qiu, W., Mu, W., Chai, K., Cao, Y., Wang, G., & Lv, G. (2022) · Hepatology International · doi:10.1007/s12072-022-10443-3 · Cited by 39
“Mendelian randomization (MR) is reported using the STROBE-MR (STrengthening the Reporting of OBservational studies in Epidemiology – Mendelian randomization) guidelines and should be performed following three basic assumptions: [1] relevance criterion: genetic instruments should be closely associated with the exposure…”
BackgroundMethodKim, H. Y., & Rinella, M. E. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0083 · Cited by 37
Lanthier, N., & Delzenne, N. M. (2022) · Cells · doi:10.3390/cells11172718 · Cited by 36
Self-citationThe immune response as a therapeutic target in non-alcoholic fatty liver disease
Ortiz‐López, N., Fuenzalida, C., Dufeu, M. S., Pinto-León, A., Escobar, A. F., Poníachik, J., Roblero, J. P., Valenzuela-Pérez, L., & Beltrán, C. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954869 · Cited by 40
Lu, R., Liu, Y., & Hong, T. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15014 · Cited by 40
“Very recently, another pan-PPAR agonist lanifibranor has been reported to alleviate steatohepatitis and fibrosis in patients with NASH in a phase II trial.(68) Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodiumglucose co-transporter-2 (SGLT2) inhibitors are also believed to be beneficial for NAFLD/NASH.”
BackgroundBandyopadhyay, S. K., Samajdar, S. S., & Das, S. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102174 · Cited by 36
Recent Advances in miRNA-Based Therapy for MASLD/MASH and MASH-Associated HCC
Carpi, S., Daniele, S., de Almeida, J. F. M., & Gabbia, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212229 · Cited by 41
“The pan-PPAR agonist lanifibranor has been shown to effectively reduce the SAF-A score (part of the Steatosis, Activity, Fibrosis scoring system) in a phase 2b trial, encouraging studies on PPAR agonists [3,53].”
Zhou, X., Fan, Q.-Y., Byrne, C. D., Targher, G., Muthiah, M. D., Huang, D. Q., Chen, Q., Noureddin, M., Li, W., Ratziu, V., et al. (2025) · Gut · doi:10.1136/gutjnl-2025-337431 · Cited by 44
Self-citationPharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart–liver co-management
Zhou, X., Lazarus, J. V., Krittanawong, C., Targher, G., Byrne, C. D., Younossi, Z. M., Tacke, F., Chen, Q., Mantzoros, C. S., Tilg, H., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00323-1 · Cited by 50
Binet, Q., Loumaye, A., Preumont, V., Thissen, J., Hermans, M. P., & Lanthier, N. (2022) · Acta gastro-enterologica belgica · doi:10.51821/85.2.9775 · Cited by 45
Self-citationYan, M., Man, S., Ma, L., & Gao, W. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155264 · Cited by 35
Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD
Vitulo, M., Gnodi, E., Rosini, G., Meneveri, R., Giovannoni, R., & Barisani, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612748 · Cited by 37
“Lanifibranor has also gone through phase 2 trials [203,204], evaluating its efficacy in NASH patients.”
BackgroundRoles and Mechanisms of Choline Metabolism in Nonalcoholic Fatty Liver Disease and Cancers
Chen, X., Qiu, W., Ma, X., Ren, L., Feng, M., Hu, S., Xue, C., & Chen, R. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2905182 · Cited by 37
“[41,67–74]) [31,64].”
BackgroundHu, Y., Sun, C., Chen, Y., Liu, Y., & Fan, J. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00123 · Cited by 61
“39 Therefore, a phase 3 study examining the efficacy and safety of lanifibranor in adult patients with MASH and fibrosis stages F2 and F3 (NATiV3) is currently underway (NCT04849728).”
BackgroundPathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets
Santos‐Laso, Á., Gutiérrez‐Larrañaga, M., Alonso‐Peña, M., Medina, J. M., Iruzubieta, P., Arias, M., López‐Hoyos, M., & Crespo, J. (2021) · Biomedicines · doi:10.3390/biomedicines10010046 · Cited by 40
Molecular Aspects of MAFLD—New Insights on Pathogenesis and Treatment
Filipović, B. F., Marjanovic-Haljilji, M., Mijac, D. D., Lukić, S., Kapor, S., Kapor, S., Starčević, A., Popovic, D. D., & Djoković, A. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45110573 · Cited by 37
Puengel, T., & Tacke, F. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2374463 · Cited by 34
“…available data indicate that single PPAR isotype-targeted approaches for the treatment of MASH especially lack antifibrotic efficacy, leading to the development and exploration of dual (e.g. elafibranor [α/δ] [36] or saroglitazar [α/γ]) [37] or pan-PPAR agonists (e.g. lanifibranor) [38].”
The role of macrophages in liver fibrosis: composition, heterogeneity, and therapeutic strategies
Ma, X., Qiu, J., Zou, S., Tan, L., & Miao, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1494250 · Cited by 35
Metadata
- Authors
- Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., Lanthier, N., Alkhouri, N., Moreno, C., Schattenberg, J. M., Stefanova-Petrova, D., Vonghia, L., Rouzier, R., Guillaume, M., Hodge, A., Romero-Gómez, M., Huot-Marchand, P., Baudin, M., Richard, M.-P., Abitbol, J.-L., Broqua, P., Junien, J.-L., & Abdelmalek, M. F.
- Affiliations
- Cliniques Universitaires Saint-Luc (BE)
- From Antwerp University Hospital and the Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp (S.M.F., L.V.), and Service d’Hépato-Gastroentérologie, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (N.L.) and Cliniques Universitaires de Bruxelles–Hôpital Erasme, Université Libre de Bruxelles (C.M.), Brussels — all in Belgium; the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom (P. Bedossa, Q.M.A.); Pitie–Salpétriêre Hospital, Institute of Cardiometabolism and Nutrition, Sorbonne Université, Paris (V.R.), Centre Hospitalier Universitaire Rangueil, Toulouse (M.G.), and Inventiva Pharma, Daix (P.H.-M., M.B., M.-P.R., J.-L.A., P. Broqua, J.-L.J.) — all in France; the Division of Gastroenterology, Department of Medical Sciences, University of Turin, Turin, Italy (E.B.); Virginia Commonwealth University, Richmond (A.J.S.); the University of California San Diego, La Jolla (R.L.); Pinnacle ...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-10-21
- Volume
- 385
- Issue
- 17
- Pages
- 1547-1558
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3207086349
- Cited by
- 801
- References
- 33
- Citations by year
- 2026: 171 · 2025: 197 · 2024: 156 · 2023: 150 · 2022: 119 · 2021: 7
- FWCI
- 77.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- HAL (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by-nc-nd)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Inventiva Pharma S.A., Daix, France
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- lanifibranor, nonalcoholic steatohepatitis, liver fibrosis regression, NASH resolution, type 2 diabetes, dose comparison, liver enzymes, PPAR agonists, fibrosis stage
- MeSH terms
- Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Liver Cirrhosis, Male, Middle Aged, Severity of Illness Index, Sulfonamides, Body Mass Index, Peroxisome Proliferator-Activated Receptors, Benzothiazoles, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.